Oncovita

Oncovita is a biotechnology company developing a disruptive virus-derived vaccine technology for the treatment of various types of cancer. Our MeasovirTM platform is based on the development of a safe, highly immunogenic measles virus vaccine, which has been clinically proven to have oncolytic potential. This technology leverages the natural anti-cancer and immunogenic properties of this harmless vaccine, making it a versatile platform for producing effective new cancer therapies and vaccines.We believe that this therapy, based on biologics derived from the safest human childhood vaccine, will be widely accepted by patients and doctors. This technology will become part of a new generation of revolutionary cancer treatments, providing patients and doctors with therapeutic options that not only positively impact survival but also quality of life.